| Literature DB >> 35407452 |
Robert Irzmański1, Renata Glowczynska2, Maciej Banach3, Dominika Szalewska4, Ryszard Piotrowicz5,6, Ilona Kowalik5, Michael J Pencina7, Wojciech Zareba8, Piotr Orzechowski9, Slawomir Pluta10, Zbigniew Kalarus10, Grzegorz Opolski2, Ewa Piotrowicz9.
Abstract
AIMS: The objective of the study was to evaluate the effects of individually prescribed hybrid comprehensive telerehabilitation (HCTR) implemented at patients' homes on left ventricular (LV) diastolic function in heart failure (HF) patients. METHODS ANDEntities:
Keywords: diastolic function; heart failure with reduced ejection fraction; hybrid telerehabilitation
Year: 2022 PMID: 35407452 PMCID: PMC8999786 DOI: 10.3390/jcm11071844
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Study flow with algorithm for estimation of LV filling pressures and grading LV diastolic function in patients with HFrEF.
Baseline characteristics.
| MDD ( | SDD ( | |||||
|---|---|---|---|---|---|---|
| HCTR-MDD | UC-MDD | HCTR-SDD | UC-SDD | |||
| Males. | 151 (89.9) | 131 (91.6) | 0.602 | 59 (88.1) | 57 (86.4) | 0.770 |
| Age (years). mean ± SD | 60.9 ± 10.8 | 60.9 ± 10.3 | 0.977 | 62.3 ± 13.6 | 62.6 ± 10.2 | 0.911 |
| Left Ventricular Ejection Fraction (%). | 32.7 ± 6.2 | 32.2 ± 6.7 | 0.552 | 27.8 ± 6.3 | 27.7 ± 7.4 | 0.931 |
| BSA (m2) | 2.01 ± 0.22 | 2.06 ± 0.21 | 0.038 | 1.93 ± 0.20 | 1.96 ± 0.20 | 0.419 |
| Etiology of heart failure. | ||||||
| Ischaemic | 117 (69.6) | 90 (62.9) | 0.212 | 43 (64.2) | 45 (68.2) | 0.626 |
| Non-ischeamic | 51 (30.4) | 53 (37.1) | 24 (35.8) | 21 (31.8) | ||
| Previous medical history. | ||||||
| Coronary artery disease | 115 (65.4) | 88 (61.5) | 0.202 | 44 (65.7) | 45 (68.2) | 0.758 |
| Myocardial infarction | 104 (61.9) | 81 (56.6) | 0.346 | 44 (65.7) | 39 (59.1) | 0.433 |
| Angioplasty | 79 (47.0) | 66 (46.1) | 0.878 | 33 (49.2) | 36 (54.5) | 0.541 |
| Coronary artery bypass grafting | 25 (14.9) | 21 (11.7) | 0.961 | 11 (16.4) | 8 (12.1) | 0.480 |
| Hypertension | 101 (60.1) | 97 (67.8) | 0.159 | 34 (50.7) | 45 (68.2) | 0.041 |
| Stroke | 9 (5.4) | 7 (4.9) | 0.854 | 2 (3.0) | 8 (12.1) | 0.055 |
| Chronic kidney disease | 21 (12.5) | 19 (13.3) | 0.836 | 18 (26.9) | 14 (21.2) | 0.446 |
| Hyperlipidemia | 85 (50.6) | 63 (44.1) | 0.250 | 31 (46.3) | 27 (40.9) | 0.533 |
| Diabetes | 56 (33.3) | 47 (32.9) | 0.931 | 21 (31.3) | 24 (36.4) | 0.541 |
| Functional status | ||||||
| NYHA I. | 19 (11.3) | 32 (22.4) | 0.007 | 8 (11.9) | 3 (4.5) | 0.254 |
| NYHA II. | 127 (75.6) | 85 (59.4) | 45 (67.2) | 45 (68.2) | ||
| NYHA III. | 22 (13.1) | 26 (18.2) | 14 (20.9) | 18 (27.3) | ||
| Treatment | ||||||
| Beta-blocker | 161 (95.8) | 137 (95.8) | 0.990 | 63 (94.0) | 66 (100) | 0.119 |
| ACEI/ARB | 159 (94.6) | 137 (95.8) | 0.634 | 58 (86.6) | 58 (87.9) | 0.821 |
| Digoxin | 9 (5.4) | 5 (3.5) | 0.430 | 8 (11.9) | 5 (7.6) | 0.397 |
| Loop diuretics | 116 (69.0) | 100 (69.9) | 0.866 | 52 (77.6) | 61 (92.4) | 0.017 |
| Spironolactone/eplerenone | 138 (82.1) | 118 (82.5) | 0.931 | 54 (80.6) | 53 (80.3) | 0.966 |
| Aspirin/clopidogrel | 121 (72.0) | 89 (62.2) | 0.066 | 37 (55.2) | 43 (65.1) | 0.243 |
| Anticoagulants | 23 (13.7) | 22 (15.4) | 0.672 | 19 (28.4) | 18 (27.3) | 0.889 |
| Statins | 146 (86.9) | 120 (83.9) | 0.455 | 50 (74.6) | 52 (78.8) | 0.570 |
| CIEDs | 122 (72.6) | 117 (81.8) | 0.055 | 58 (86.6) | 54 (81.8) | 0.453 |
| Implantable cardioverter-defibrillator | 75 (61.5) | 78 (66.7) | 0.482 | 39 (67.2) | 33 (61.1) | 0.310 |
| CRT-P | 3 (2.5) | 2 (1.7) | 0 | 0 | ||
| CRT-D | 42 (34.4) | 37 (31.6) | 19 (32.8) | 19 (35.2) | ||
Abbreviations: NYHA—New York Heart Association class; ACEI—angiotensin-converting enzyme inhibitors; ARB—angiotensin receptor blockers; CIEDs—cardiovascular implantable electronic devices; CRT-P—cardiac resynchronization therapy; CRT-D—cardiac resynchronization therapy and cardioverter-defibrillator; DM—diabetes mellitus; BSA—body surface area; HCTR-MD—patients in hybrid comprehensive telerehabilitation arm with mild diastolic dysfunction; HCTR-SDD—patients in hybrid comprehensive telerehabilitation arm with severe diastolic dysfunction; HFrEF—heart failure with reduced ejection fraction; UC-MDD—patients in usual care arm with mild diastolic dysfunction; UC-SDD—patients in usual care arm with severe diastolic dysfunction.
Baseline parameters of echocardiographic parameters.
| MDD ( | SDD ( | |||||
|---|---|---|---|---|---|---|
| HCTR-MDD | UC-MDD | HCTR-SDD | UC-SDD | |||
| E | 0.53 ± 0.16 | 0.55 ± 0.17 | 0.421 | 0.93 ± 0.24 | 0.93 ± 0.24 | 0.962 |
| A | 0.70 ± 0.17 | 0.73 ± 0.17 | 0.219 | 0.39 ± 0.18 | 0.43 ± 0.18 | 0.224 |
| E/A | 0.79 ± 0.29 | 0.79 ± 0.33 | 0.983 | 2.63 ± 0.91 | 2.43 ± 0.97 | 0.267 |
| DTE | 230 ± 59 | 222 ± 64 | 0.241 | 164 ± 49 | 172 ± 54 | 0.432 |
| E/E’ lat | 8.09 ± 3.07 | 8.03 ± 3.02 | 0.883 | 17.3 ± 8.6 | 15.4 ± 7.1 | 0.223 |
| E/E’ med | 9.53 ± 3.2 | 9.50 ± 3.07 | 0.935 | 19.1 ± 10.0 | 22.5 ± 10.1 | 0.067 |
| E/E’ avg | 8.81 ± 2.61 | 8.77 ± 2.46 | 0.904 | 18.2 ± 8.3 | 19.0 ± 7.6 | 0.586 |
| LA | 42.8 ± 6.0 | 43.2 ± 5.8 | 0.546 | 46.3 ± 7.0 | 47.6 ± 6.4 | 0.254 |
| LAA | 23.0 ± 4.8 | 24.0 ± 5.9 | 0.113 | 28.5 ± 6.2 | 28.2 ± 6.8 | 0.854 |
| TR velocity | 2.03 ± 0.46 | 2.04 ± 0.49 | 0.894 | 2.8 ± 0.7 | 2.9 ± 0.7 | 0.557 |
| EF | 32.8 ± 6.1 | 32.1 ± 6.7 | 0.330 | 27.9 ± 6.4 | 28.0 ± 7.4 | 0.937 |
| E/A ≤ 0.8 ( | 112 (66.7) | 98 (68.5) | 0.727 | 1 (1.5) | 1 (1.5) | 0.185 |
| E/A 0.8–2 ( | 56 (33.3) | 45 (31.5) | 3 (4.5) | 9 (13.6) | ||
| E/A > 2 ( | 0 | 0 | 63 (94.0) | 56 (84.8) | ||
| DTE ≤ 160 ( | 15 (9.0) | 18 (12.6) | 0.004 | 37 (56.1) | 34 (53.1) | 0.870 |
| DTE 160–200 ( | 26 (15.7) | 10 (29.4) | 17 (25.8) | 16 (25.0) | ||
| DTE ≥ 200 ( | 125 (75.3) | 83 (58.0) | 12 (18.2) | 25 (21.9) | ||
| E/E’ avg > 14 ( | 1 (0.6) | 2 (1.4) | 0.595 | 44 (65.7) | 49 (75.4) | 0.221 |
| TR velocity > 2.8 ( | 1 (0.6) | 0 (0) | 1.00 | 23 (43.4) | 27 (51.9) | 0.382 |
Abbreviations: HCTR-MDD—patients in hybrid comprehensive telerehabilitation arm with mild diastolic dysfunction; HCTR-SDD– patients in hybrid comprehensive telerehabilitation arm with severe diastolic dysfunction; HFrEF—heart failure with reduced ejection fraction; UC-MDD—patients in usual care arm with mild diastolic dysfunction; UC-SDD—patients in usual care arm with severe diastolic dysfunction; LVEF—Left Ventricular Ejection Fraction; E—early diastolic mitral inflow velocity; A—late diastolic mitral inflow velocity; DTE—deceleration time of E wave; E’ med—E’ velocity at medial wall; E’ lat—E’ velocity at lateral wall; E/E’ avg—average value of E/E’ at medial and lateral wall of the left ventricle; TR velocity—tricuspid regurgitation (TR) jet velocity; LA—left atrium diameter; LAA—left atrium area.
Changes from baseline to 9 weeks in echocardiographic parameters (adjusted for baseline measure, body Surface area, hypertension, loop diuretics, NYHA class).
| MDD ( | SDD ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HCTR-MDD | UC-MDD | Difference | HCTR-SDD | UC-SDD | Difference | ||||
| Δ 9 week—baseline [95% CI] * | Δ 9 week—baseline [95% CI] * | ||||||||
| E [m/s] | 0.01 | −0.02 | 0.03 | 0.526 | 0.01 | 0.03 | −0.02 | 0.864 | 0.163 |
| A | 0.03 | −0.03 | 0.06 | <0.010 | −0.01 | 0.02 | −0.03 | 0.648 | 0.008 |
| E/A | −0.03 | −0.02 | −0.01 | 0.992 | −0.03 | 0.00 | −0.03 | 0.989 | 0.844 |
| DTE | 7.7 | 4.5 | 3.2 | 0.973 | −23.9 | −22.6 | −1.3 | 0.999 | 0.744 |
| E/E’ lat | −0.08 | −0.27 | 0.19 | 0.989 | 2.07 | 1.42 | 0.65 | 0.901 | 0.684 |
| E/E’ med | −0.78 | −0.97 | 0.19 | 0.993 | 1.86 | 2.38 | −0.52 | 0.965 | 0.587 |
| E/E’ avg | −0.32 | −0.51 | 0.19 | 0.988 | 1.79 | 1.55 | 0.24 | 0.993 | 0.958 |
| LA LAX | 0.03 | −0.66 | 0.69 | 0.597 | 0.72 | −0.24 | 0.96 | 0.670 | 0.789 |
| LAA 4CH | −0.24 | −0.69 | 0.45 | 0.764 | 1.70 | 1.14 | 0.56 | 0.875 | 0.904 |
| TR velocity | −0.17 | −0.07 | −0.10 | 0.462 | 0.18 | −0.05 | 0.23 | 0.106 | 0.007 |
| EF | 2.17 | 1.14 | 1.03 | 0.111 | 1.06 | 1.27 | −0.21 | 0.990 | 0.138 |
Abbreviations: HCTR-MDD—patients in hybrid comprehensive telerehabilitation arm with mild diastolic dysfunction; HCTR-SDD–patients in hybrid comprehensive telerehabilitation arm with severe diastolic dysfunction; HFrEF—heart failure with reduced ejection fraction; UC-MDD—patients in usual care arm with mild diastolic dysfunction; UC-SDD—patients in usual care arm with severe diastolic dysfunction; LVEF—left ventricular ejection fraction; E—early diastolic mitral inflow velocity; A—late diastolic mitral inflow velocity; DTE—deceleration time of E wave; E’ med—E’ velocity at medial wall; E’ lat—E’ velocity at lateral wall; E/E’ avg—average value of E/E’ at medial and lateral wall of the left ventricle; TR velocity—tricuspid regurgitation (TR) jet velocity; LA—left atrium diameter; LAA—left atrium area. * regarding Difference [95% CI].
Figure 2Kaplan–Meier Plot of all-cause mortality-free survivals in subgroups regarding diastolic function and rehabilitation.
Figure 3Kaplan–Meier plot of cardiovascular mortality-free survival in subgroups regarding diastolic function and rehabilitation.
Figure 4Kaplan–Meier plot of cardiovascular hospitalization in subgroups regarding diastolic function and rehabilitation.
Figure 5Kaplan–Meier plot of heart failure hospitalization in subgroups regarding diastolic function and rehabilitation.